Immuneering CSO buys 6,035 IMRX shares
Immuneering Corp's Chief Scientific Officer Brett Matthew Hall reported an open-market purchase of Class A Common Stock.
Rhea-AI Filing Summary
Immuneering Corp's Chief Scientific Officer Brett Matthew Hall reported an open-market purchase of Class A Common Stock. On June 15, 2026, he bought 6,035 shares at a weighted average price of $4.15 per share. Following this transaction, he directly owns 382,531 shares of Immuneering Corp stock. The filing notes the trade was executed through a broker-dealer in multiple transactions at prices ranging from $4.146 to $4.15 per share, with the reported price representing the weighted average.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 6,035 shares
Net Buy
1 txn
Insider
Hall Brett Matthew
Role
CHIEF SCIENTIFIC OFFICER
Bought
6,035 shs ($25K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Class A Common Stock | 6,035 | $4.15 | $25K |
Holdings After Transaction:
Class A Common Stock — 382,531 shares (Direct)
Footnotes (1)
- F1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.146 to $4.15. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.
Key Figures
Shares purchased: 6,035 shares
Purchase price: $4.15 per share
Post-transaction holdings: 382,531 shares
+2 more
5 metrics
Shares purchased
6,035 shares
Open-market purchase on June 15, 2026
Purchase price
$4.15 per share
Weighted average purchase price for acquired shares
Post-transaction holdings
382,531 shares
Direct holdings after the June 15, 2026 transaction
Trade price range
$4.146–$4.15 per share
Range of execution prices across multiple trades
Net buy shares
6,035 shares
Net change in position from this Form 4
Key Terms
open-market purchase, weighted average purchase price, broker-dealer, Form 4
4 terms
open-market purchase financial
"he bought 6,035 shares at a weighted average price in an open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average purchase price financial
"The price reported in this column reflects the weighted average purchase price."
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
broker-dealer financial
"This transaction was executed in multiple trades through a broker-dealer at prices ranging"
A broker-dealer is a licensed firm or individual that both executes trades on behalf of clients (acting as a broker) and buys or sells securities for its own account (acting as a dealer). Investors care because broker-dealers provide the plumbing of markets — they place orders, hold or move cash and securities, offer research or advice, and their stability and fees directly affect trade execution, costs, and the safety of client funds; think of them as a combined travel agent and taxi for your investments.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Immuneering Corp (IMRX) report on this Form 4?
Immuneering Corp reported that Chief Scientific Officer Brett Matthew Hall made an open-market purchase of Class A Common Stock. He acquired 6,035 shares on June 15, 2026 at a weighted average price of $4.15 per share, based on multiple broker-executed trades.
At what prices did the Immuneering Corp (IMRX) insider trades occur on June 15, 2026?
The trades were executed through a broker-dealer in multiple transactions at prices ranging from $4.146 to $4.15 per share. The Form 4 reports a weighted average purchase price of $4.15 for the 6,035 shares of Immuneering Corp Class A Common Stock acquired that day.
Who is the insider involved in the latest Immuneering Corp (IMRX) Form 4 filing?
The insider is Brett Matthew Hall, Immuneering Corp’s Chief Scientific Officer. He reported an open-market purchase of 6,035 shares of Class A Common Stock on June 15, 2026, at a weighted average price of $4.15 per share, increasing his direct holdings to 382,531 shares.
Was the Immuneering Corp (IMRX) insider transaction an open-market purchase or another type?
The transaction was an open-market purchase of Class A Common Stock, coded as “P” on the Form 4. Brett Matthew Hall bought 6,035 shares at a weighted average price of $4.15, with trades executed through a broker-dealer across a small price range on June 15, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
